Celsion Corporation(CLSN)- NASDAQ
  • Mon, Sep. 12, 9:15 AM
    | Mon, Sep. 12, 9:15 AM
  • Fri, Aug. 19, 11:03 AM
    | Fri, Aug. 19, 11:03 AM | 3 Comments
  • Mon, Aug. 15, 10:02 AM
    • Celsion (CLSN +5%) Q2 results: Revenues: $0.1M (unch); Operating Loss: ($4.7M) (+9.6%); Net Loss: ($4.5M) (+21.1%); Loss Per Share: ($0.19) (+29.6%); Quick Assets: $12.3M (+32.3%).
    • No guidance given.
    | Mon, Aug. 15, 10:02 AM
  • Mon, Aug. 15, 9:12 AM
    | Mon, Aug. 15, 9:12 AM | 1 Comment
  • Mon, Aug. 15, 9:04 AM
    • Celsion (NASDAQ:CLSN): Q2 EPS of -$0.19 beats by $0.02.
    • Revenue of $0.13M (flat Y/Y) beats by $0.05M.
    • Shares +7.5% PM.
    • Press Release
    | Mon, Aug. 15, 9:04 AM
  • Mon, Jul. 25, 9:17 AM
    | Mon, Jul. 25, 9:17 AM | 1 Comment
  • Mon, Jun. 13, 4:16 PM
    • Celsion (NASDAQ:CLSN) enters into a definitive agreement with an institutional investor to sell $6M of stock or pre-funded warrants in a registered direct offering.
    • The company has agreed to sell ~4.4M shares of common stock (or pre-funded warrants) at $1.36 a share or warrant share. For each share bought, the investor will receive a Series A warrant to purchase 0.5 of a share of common, a Series C warrant to purchase one share of common and a Series D warrant to purchase 0.5 of a share of common, all at an exercise price of $1.40 per common share.
    • The Series A warrants are exercisable six months following issuance terminating 5 1/2 years following issuance, the Series C warrants are exercisable six months following issuance terminating one year following issuance while the Series D warrants are only exercisable upon the exercise of the Series C warrants. They are initially exercisable six months following issuance and terminate 5 1/2 years following issuance.
    • Closing date is June 16.
    | Mon, Jun. 13, 4:16 PM | 2 Comments
  • Mon, May 16, 8:36 AM
    • Celsion (CLSN) Q1 results: Revenues: $0.1M (unch); R&D Expense: $3.4M (-24.4%); SG&A: $1.9M (-5.0%); Operating Loss: ($5.2M) (+18.8%); Net Loss: ($5.7M) (+18.6%); Loss Per Share: ($0.24) (+31.4%); Quick Assets: $14.3M (+53.8%).
    • No guidance given.
    | Mon, May 16, 8:36 AM
  • Mon, May 16, 8:05 AM
    • Celsion (NASDAQ:CLSN): Q1 EPS of -$0.24 misses by $0.03.
    • Revenue of $0.13M (flat Y/Y) beats by $0.05M.
    • Press Release
    | Mon, May 16, 8:05 AM
  • Tue, Apr. 19, 9:17 AM
    | Tue, Apr. 19, 9:17 AM | 2 Comments
  • Wed, Mar. 30, 9:22 AM
    • Celsion Corp. (CLSN) FY15 results: Revenues: $0.5M (unch); R&D Expense: $14.7M (-2.0%); SG&A: $6.7M (-24.7%); Operating Loss: ($20.8M) (+15.8%); Net Loss: ($22.5M) (+11.8%); Loss Per Share: ($1.03) (+25.4%); Quick Assets: $9.3M (-26.8%).
    • No guidance given.
    | Wed, Mar. 30, 9:22 AM
  • Wed, Mar. 30, 8:05 AM
    • Celsion (NASDAQ:CLSN): FY15 EPS of -$1.03
    • Revenue of $0.5M (flat Y/Y)
    | Wed, Mar. 30, 8:05 AM
  • Dec. 16, 2015, 9:14 AM
    | Dec. 16, 2015, 9:14 AM
  • Nov. 12, 2015, 6:51 AM
    • Celsion (NASDAQ:CLSN) shares will begin trading on the TASE today. Based on its market cap, it will be included in two TASE equity indexes: the TA-BlueTech and TA-Biomed.
    • Chairman, President & CEO Michael Tardugno says, "We believe that the dual listing on the TASE will help us to open a new access point for our shares in the Israeli market that is becoming a center for biomed and emerging technology companies. The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving or accessibility to Israeli investors."
    | Nov. 12, 2015, 6:51 AM | 1 Comment
  • Nov. 5, 2015, 10:40 AM
    • Celsion Corp. (CLSN -1%) Q3 results: Revenues: $0.1M (unch); R&D Expense: $2.9M (-37.0%); SG&A: $1.5M (-25.0%); Operating Loss: ($4.2M) (+37.3%); Net Loss: ($4.3M) (+37.7%); Loss Per Share: ($0.19) (+52.5%); Quick Assets: $7.6M (-40.2%).
    • No guidance given.
    | Nov. 5, 2015, 10:40 AM
  • Nov. 5, 2015, 8:06 AM
    • Celsion (NASDAQ:CLSN): Q3 EPS of -$0.19 may not be comparable to consensus of -$0.26.
    • Revenue of $0.13M (flat Y/Y) beats by $0.02M.
    | Nov. 5, 2015, 8:06 AM